See more : Blue Coast Hotels Limited (BLUECOAST.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Provention Bio, Inc. (PRVB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Provention Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- PepperLime Health Acquisition Corporation (PEPL) Income Statement Analysis – Financial Results
- Quanergy Systems, Inc. (QNGYQ) Income Statement Analysis – Financial Results
- Rendong Holdings Co., Ltd. (002647.SZ) Income Statement Analysis – Financial Results
- Microsoft Corporation (MSFT) Income Statement Analysis – Financial Results
- Osaka Steel Co., Ltd. (5449.T) Income Statement Analysis – Financial Results
Provention Bio, Inc. (PRVB)
About Provention Bio, Inc.
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 12.90M | 1.40M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 512.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 12.38M | 1.40M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 96.03% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 75.80M | 69.63M | 66.36M | 36.36M | 22.65M | 7.68M |
| General & Administrative | 64.11M | 47.35M | 33.33M | 8.01M | 4.17M | 1.46M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 64.11M | 47.35M | 33.33M | 8.01M | 4.17M | 1.46M |
| Other Expenses | 627.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 140.54M | 116.97M | 99.69M | 44.37M | 26.81M | 9.14M |
| Cost & Expenses | 141.06M | 116.97M | 99.69M | 44.37M | 26.81M | 9.14M |
| Interest Income | 2.24M | 146.00K | 583.00K | 1.09M | 669.00K | 131.50K |
| Interest Expense | 1.04M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.47M | 387.00K | 33.00K | -16.00K | 149.00K | 6.50K |
| EBITDA | -124.69M | -115.58M | -99.69M | -44.37M | -26.67M | -9.13M |
| EBITDA Ratio | -966.98% | -8,285.16% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -128.16M | -115.58M | -99.69M | -44.37M | -26.81M | -9.14M |
| Operating Income Ratio | -993.88% | -8,285.16% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.20M | 146.00K | 583.00K | 1.09M | 149.00K | 6.50K |
| Income Before Tax | -126.96M | -115.43M | -99.10M | -43.29M | -26.67M | -9.13M |
| Income Before Tax Ratio | -984.54% | -8,274.70% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -13.39M | -1.00M | -523.00K | -1.09M | -187.00K | -131.50K |
| Net Income | -113.57M | -114.43M | -98.58M | -42.20M | -26.48M | -9.13M |
| Net Income Ratio | -880.69% | -8,203.01% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.52 | -1.81 | -1.88 | -1.04 | -1.18 | -0.27 |
| EPS Diluted | -1.52 | -1.81 | -1.88 | -1.04 | -1.18 | -0.27 |
| Weighted Avg Shares Out | 74.72M | 63.10M | 52.46M | 40.75M | 22.44M | 33.88M |
| Weighted Avg Shares Out (Dil) | 74.72M | 63.10M | 52.46M | 40.75M | 22.44M | 33.88M |
Provention Bio to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
Provention Bio Provides Update on the Potential Timing of Teplizumab At-Risk Type 1 Diabetes (T1D) Biologics License Application (BLA) Resubmission
7 Biotech Stocks to Buy That Have Millionaire-Maker Potential
Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q2 2021 Results - Earnings Call Transcript
Provention Bio Reports Second Quarter 2021 Financial Results and Provides Business Update
Provention Bio: Blood (Glucose) In The Streets
Provention Bio to Report Second Quarter 2021 Financial Results on August 5, 2021
PRVB Final Deadline Today: Rosen, Trusted Investor Counsel, Encourages Provention Bio, Inc. Investors to Secure Counsel Before Important July 20 Deadline in Securities Class Action - PRVB
PRVB Final Deadline Today: Rosen, Trusted Investor Counsel, Encourages Provention Bio, Inc. Investors to Secure Counsel Before Important July 20 Deadline in Securities Class Action - PRVB
DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Source: https://incomestatements.info
Category: Stock Reports